Skip to main content
Top
Published in: Arthritis Research & Therapy 6/2010

Open Access 01-12-2010 | Research article

Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis

Authors: Staffan Larsson, Martin Englund, André Struglics, L Stefan Lohmander

Published in: Arthritis Research & Therapy | Issue 6/2010

Login to get access

Abstract

Introduction

Aggrecanase cleavage at the 392Glu-393Ala bond in the interglobular domain (IGD) of aggrecan, releasing N-terminal 393ARGS fragments, is an early key event in arthritis and joint injuries. We determined whether synovial fluid (SF) levels of ARGS-aggrecan distinguish subjects with progressive radiographic knee osteoarthritis (ROA) from those with stable or no ROA.

Methods

We studied 141 subjects who, at examination A, had been given meniscectomies an average of 18 years earlier (range, 15 to 22 years). Seventeen individuals without surgery, and without known injury to the menisci or cruciate ligaments, were used as references. At examinations A and B, with a mean follow-up time of 7.5 years, we obtained SF and standing tibiofemoral and skyline patellofemoral radiographs. SF ARGS-aggrecan was measured with an electrochemiluminescence immunoassay, and we graded radiographs according to the OARSI atlas. The association between SF ARGS levels at examination A and progression of radiographic features of knee OA between examinations A and B was assessed by using logistic regression adjusted for age, gender, body mass index, and time between examinations, and stratified by ROA status at examination A.

Results

We found a weak negative association between SF ARGS concentrations and loss of joint space: the likelihood of progression of radiographic joint space narrowing decreased 0.9 times per picomole per milliliter increase in ARGS (odds ratio (OR) 0.89; 95% confidence interval (CI), 0.79 to 0.996). In subjects with and without preexisting ROA at examination A, the association was OR, 0.96; 0.81 to 1.13; and 0.77; 0.62 to 0.95, respectively. Average levels of SF ARGS 18 years after meniscectomy were no different from those of reference subjects and were not correlated to radiographic status at examination A.

Conclusions

In subjects with previous knee meniscectomy but without ROA, levels of SF ARGS-aggrecan were weakly and inversely associated with increased loss of joint space over a period of 7.5 years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sandy JD: Proteolytic degradation of normal and osteoarthritic cartilage matrix. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 82-92. 2 Sandy JD: Proteolytic degradation of normal and osteoarthritic cartilage matrix. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 82-92. 2
2.
go back to reference Fosang AJ, Last K, Maciewicz RA: Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest. 1996, 98: 2292-2299. 10.1172/JCI119040.PubMedCentralCrossRefPubMed Fosang AJ, Last K, Maciewicz RA: Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest. 1996, 98: 2292-2299. 10.1172/JCI119040.PubMedCentralCrossRefPubMed
3.
go back to reference Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001, 60: 619-626. 10.1136/ard.60.6.619.PubMedCentralCrossRefPubMed Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001, 60: 619-626. 10.1136/ard.60.6.619.PubMedCentralCrossRefPubMed
4.
go back to reference Lohmander LS, Atley LM, Pietka TA, Eyre DR: The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003, 48: 3130-3139. 10.1002/art.11326.CrossRefPubMed Lohmander LS, Atley LM, Pietka TA, Eyre DR: The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum. 2003, 48: 3130-3139. 10.1002/art.11326.CrossRefPubMed
5.
go back to reference Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005, 434: 644-648. 10.1038/nature03369.CrossRefPubMed Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005, 434: 644-648. 10.1038/nature03369.CrossRefPubMed
6.
go back to reference Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ: ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005, 434: 648-652. 10.1038/nature03417.CrossRefPubMed Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, Fourie AM, Fosang AJ: ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005, 434: 648-652. 10.1038/nature03417.CrossRefPubMed
7.
go back to reference Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ: Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2006, 14: 1189-1195. 10.1016/j.joca.2006.04.009.CrossRefPubMed Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ: Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2006, 14: 1189-1195. 10.1016/j.joca.2006.04.009.CrossRefPubMed
8.
go back to reference Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM: Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009, 60: 1372-1380. 10.1002/art.24473.CrossRefPubMed Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM: Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum. 2009, 60: 1372-1380. 10.1002/art.24473.CrossRefPubMed
9.
go back to reference Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C: Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage. 2009, 17: 384-389. 10.1016/j.joca.2008.07.009.CrossRefPubMed Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C: Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage. 2009, 17: 384-389. 10.1016/j.joca.2008.07.009.CrossRefPubMed
10.
go back to reference Larsson S, Lohmander LS, Struglics A: Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther. 2009, 11: R92-10.1186/ar2735.PubMedCentralCrossRefPubMed Larsson S, Lohmander LS, Struglics A: Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther. 2009, 11: R92-10.1186/ar2735.PubMedCentralCrossRefPubMed
11.
go back to reference Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW: Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 2009, 60: 3723-3733. 10.1002/art.25002.PubMedCentralCrossRefPubMed Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW: Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum. 2009, 60: 3723-3733. 10.1002/art.25002.PubMedCentralCrossRefPubMed
12.
go back to reference Struglics A, Larsson S, Hansson M, Lohmander LS: Western blot quantification of aggrecan fragments in human synovial fluid indicates differences in fragment patterns between joint diseases. Osteoarthritis Cartilage. 2009, 17: 497-506. 10.1016/j.joca.2008.09.017.CrossRefPubMed Struglics A, Larsson S, Hansson M, Lohmander LS: Western blot quantification of aggrecan fragments in human synovial fluid indicates differences in fragment patterns between joint diseases. Osteoarthritis Cartilage. 2009, 17: 497-506. 10.1016/j.joca.2008.09.017.CrossRefPubMed
13.
go back to reference Pratta MA, Yao WQ, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003, 278: 45539-45545. 10.1074/jbc.M303737200.CrossRefPubMed Pratta MA, Yao WQ, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003, 278: 45539-45545. 10.1074/jbc.M303737200.CrossRefPubMed
14.
go back to reference Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegård D, Jordan JM, Kepler TB, Lane NE, Saxne T, Tyree B, Kraus VB: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006, 14: 723-727. 10.1016/j.joca.2006.04.001.CrossRefPubMed Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, Heinegård D, Jordan JM, Kepler TB, Lane NE, Saxne T, Tyree B, Kraus VB: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006, 14: 723-727. 10.1016/j.joca.2006.04.001.CrossRefPubMed
15.
go back to reference Kraus VB: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 2005, 17: 641-646. 10.1097/01.bor.0000174195.15421.17.CrossRefPubMed Kraus VB: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 2005, 17: 641-646. 10.1097/01.bor.0000174195.15421.17.CrossRefPubMed
16.
go back to reference Rousseau JC, Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 2007, 3: 346-356. 10.1038/ncprheum0508.CrossRefPubMed Rousseau JC, Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 2007, 3: 346-356. 10.1038/ncprheum0508.CrossRefPubMed
17.
go back to reference Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004, 50: 2471-2478. 10.1002/art.20332.CrossRefPubMed Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, Uitterlinden AG, Pols HA: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004, 50: 2471-2478. 10.1002/art.20332.CrossRefPubMed
18.
go back to reference Lohmander LS, Dahlberg L, Ryd L, Heinegård D: Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989, 32: 1434-1442. 10.1002/anr.1780321113.CrossRefPubMed Lohmander LS, Dahlberg L, Ryd L, Heinegård D: Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 1989, 32: 1434-1442. 10.1002/anr.1780321113.CrossRefPubMed
19.
go back to reference Dahlberg L, Ryd L, Heinegård D, Lohmander LS: Proteoglycan fragments in joint fluid: influence of arthrosis and inflammation. Acta Orthop Scand. 1992, 63: 417-423. 10.3109/17453679209154758.CrossRefPubMed Dahlberg L, Ryd L, Heinegård D, Lohmander LS: Proteoglycan fragments in joint fluid: influence of arthrosis and inflammation. Acta Orthop Scand. 1992, 63: 417-423. 10.3109/17453679209154758.CrossRefPubMed
20.
go back to reference Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Björnsson S, Lark MW: Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol. 1993, 20: 1362-1368.PubMed Lohmander LS, Hoerrner LA, Dahlberg L, Roos H, Björnsson S, Lark MW: Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol. 1993, 20: 1362-1368.PubMed
21.
go back to reference Saxne T, Glennås A, Kvien TK, Melby K, Heinegård D: Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum. 1993, 36: 20-25. 10.1002/art.1780360105.CrossRefPubMed Saxne T, Glennås A, Kvien TK, Melby K, Heinegård D: Release of cartilage macromolecules into the synovial fluid in patients with acute and prolonged phases of reactive arthritis. Arthritis Rheum. 1993, 36: 20-25. 10.1002/art.1780360105.CrossRefPubMed
22.
go back to reference Englund M, Roos EM, Lohmander LS: Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteen-year followup of meniscectomy with matched controls. Arthritis Rheum. 2003, 48: 2178-2187. 10.1002/art.11088.CrossRefPubMed Englund M, Roos EM, Lohmander LS: Impact of type of meniscal tear on radiographic and symptomatic knee osteoarthritis: a sixteen-year followup of meniscectomy with matched controls. Arthritis Rheum. 2003, 48: 2178-2187. 10.1002/art.11088.CrossRefPubMed
23.
go back to reference Englund M, Lohmander LS: Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum. 2004, 50: 2811-2819. 10.1002/art.20489.CrossRefPubMed Englund M, Lohmander LS: Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. Arthritis Rheum. 2004, 50: 2811-2819. 10.1002/art.20489.CrossRefPubMed
24.
go back to reference Englund M, Lohmander LS: Patellofemoral osteoarthritis coexistent with tibiofemoral osteoarthritis in a meniscectomy population. Ann Rheum Dis. 2005, 64: 1721-1726. 10.1136/ard.2005.035568.PubMedCentralCrossRefPubMed Englund M, Lohmander LS: Patellofemoral osteoarthritis coexistent with tibiofemoral osteoarthritis in a meniscectomy population. Ann Rheum Dis. 2005, 64: 1721-1726. 10.1136/ard.2005.035568.PubMedCentralCrossRefPubMed
25.
go back to reference Peterfy C, Li J, Zaim S, Duryea J, Lynch J, Miaux Y, Yu W, Genant HK: Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol. 2003, 32: 128-132. 10.1007/s00256-002-0603-z.CrossRefPubMed Peterfy C, Li J, Zaim S, Duryea J, Lynch J, Miaux Y, Yu W, Genant HK: Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol. 2003, 32: 128-132. 10.1007/s00256-002-0603-z.CrossRefPubMed
26.
go back to reference Kothari M, Guermazi A, von Ingersleben G, Miaux Y, Sieffert M, Block JE, Stevens R, Peterfy CG: Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol. 2004, 14: 1568-1573. 10.1007/s00330-004-2312-6.CrossRefPubMed Kothari M, Guermazi A, von Ingersleben G, Miaux Y, Sieffert M, Block JE, Stevens R, Peterfy CG: Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol. 2004, 14: 1568-1573. 10.1007/s00330-004-2312-6.CrossRefPubMed
27.
go back to reference Altman RD, Hochberg M, Murphy WA, Wolfe F, Lequesne M: Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995, 3 (suppl A): 3-70.PubMed Altman RD, Hochberg M, Murphy WA, Wolfe F, Lequesne M: Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage. 1995, 3 (suppl A): 3-70.PubMed
28.
go back to reference Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS: Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006, 14: 101-113. 10.1016/j.joca.2005.07.018.CrossRefPubMed Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS: Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006, 14: 101-113. 10.1016/j.joca.2005.07.018.CrossRefPubMed
29.
go back to reference Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999, 284: 1664-1666. 10.1126/science.284.5420.1664.CrossRefPubMed Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Newton RC, Magolda RL, Trzaskos JM, Arner EC: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999, 284: 1664-1666. 10.1126/science.284.5420.1664.CrossRefPubMed
30.
go back to reference Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S: Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006, 14: 702-713. 10.1016/j.joca.2006.01.012.CrossRefPubMed Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, Kumar S: Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage. 2006, 14: 702-713. 10.1016/j.joca.2006.01.012.CrossRefPubMed
31.
go back to reference Swearingen CA, Carpenter JW, Siegel R, Brittain IJ, Dotzlaf J, Durham TB, Toth JL, Laska DA, Marimuthu J, Liu C, Brown DP, Carter QL, Wiley MR, Duffin KL, Mitchell PG, Thirunavukkarasu K: Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage. 2010, 18: 1150-1158. 10.1016/j.joca.2010.06.011.CrossRefPubMed Swearingen CA, Carpenter JW, Siegel R, Brittain IJ, Dotzlaf J, Durham TB, Toth JL, Laska DA, Marimuthu J, Liu C, Brown DP, Carter QL, Wiley MR, Duffin KL, Mitchell PG, Thirunavukkarasu K: Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage. 2010, 18: 1150-1158. 10.1016/j.joca.2010.06.011.CrossRefPubMed
32.
go back to reference Deaver DR: A new non-isotopic detection system for immunoassays. Nature. 1995, 377: 758-760. 10.1038/377758a0.CrossRefPubMed Deaver DR: A new non-isotopic detection system for immunoassays. Nature. 1995, 377: 758-760. 10.1038/377758a0.CrossRefPubMed
33.
go back to reference Guglielmo-Viret V, Thullier P: Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J Immunol Methods. 2007, 328: 70-78. 10.1016/j.jim.2007.08.003.CrossRefPubMed Guglielmo-Viret V, Thullier P: Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J Immunol Methods. 2007, 328: 70-78. 10.1016/j.jim.2007.08.003.CrossRefPubMed
34.
go back to reference Chowdhury F, Williams A, Johnson P: Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009, 340: 55-64. 10.1016/j.jim.2008.10.002.CrossRefPubMed Chowdhury F, Williams A, Johnson P: Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009, 340: 55-64. 10.1016/j.jim.2008.10.002.CrossRefPubMed
35.
go back to reference Chockalingam PS, Sun W, Rivera-Bermudez MA, Zeng W, Dufield DR, Larsson S, Lohmander LS, Flannery CR, Glasson SS, Georgiadis KE, Morris EA: Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage Chockalingam PS, Sun W, Rivera-Bermudez MA, Zeng W, Dufield DR, Larsson S, Lohmander LS, Flannery CR, Glasson SS, Georgiadis KE, Morris EA: Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage
36.
go back to reference Doege KJ, Sasaki M, Kimura T, Yamada Y: Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan: human-specific repeats, and additional alternatively spliced forms. J Biol Chem. 1991, 266: 894-902.PubMed Doege KJ, Sasaki M, Kimura T, Yamada Y: Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan: human-specific repeats, and additional alternatively spliced forms. J Biol Chem. 1991, 266: 894-902.PubMed
37.
go back to reference Rizkalla G, Reiner A, Bogoch E, Poole AR: Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 1992, 90: 2268-2277. 10.1172/JCI116113.PubMedCentralCrossRefPubMed Rizkalla G, Reiner A, Bogoch E, Poole AR: Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 1992, 90: 2268-2277. 10.1172/JCI116113.PubMedCentralCrossRefPubMed
38.
go back to reference Lohmander LS, Ionescu M, Jugessur H, Poole AR: Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 1999, 42: 534-544. 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J.CrossRefPubMed Lohmander LS, Ionescu M, Jugessur H, Poole AR: Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum. 1999, 42: 534-544. 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J.CrossRefPubMed
39.
go back to reference Lohmander LS, Poole AR: Defining and validating the clinical role of molecular markers in osteoarthritis. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 468-477. 2 Lohmander LS, Poole AR: Defining and validating the clinical role of molecular markers in osteoarthritis. Osteoarthritis. Edited by: Brandt KD, Doherty M, Lohmander LS. 2003, Oxford: Oxford University Press, 468-477. 2
40.
go back to reference Simkin PA, Bassett JE: Cartilage matrix molecules in serum and synovial fluid. Curr Opin Rheumatol. 1995, 7: 346-351. 10.1097/00002281-199507000-00014.CrossRefPubMed Simkin PA, Bassett JE: Cartilage matrix molecules in serum and synovial fluid. Curr Opin Rheumatol. 1995, 7: 346-351. 10.1097/00002281-199507000-00014.CrossRefPubMed
41.
go back to reference Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L: Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage. 1998, 6: 351-361. 10.1053/joca.1998.0134.CrossRefPubMed Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L: Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage. 1998, 6: 351-361. 10.1053/joca.1998.0134.CrossRefPubMed
42.
go back to reference Saxne T, Heinegård D, Wollheim FA, Pettersson H: Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet. 1985, 2: 127-128. 10.1016/S0140-6736(85)90229-6.CrossRefPubMed Saxne T, Heinegård D, Wollheim FA, Pettersson H: Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet. 1985, 2: 127-128. 10.1016/S0140-6736(85)90229-6.CrossRefPubMed
43.
go back to reference Saxne T, Heinegård D, Wollheim FA: Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann Rheum Dis. 1986, 45: 491-497. 10.1136/ard.45.6.491.PubMedCentralCrossRefPubMed Saxne T, Heinegård D, Wollheim FA: Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid. Ann Rheum Dis. 1986, 45: 491-497. 10.1136/ard.45.6.491.PubMedCentralCrossRefPubMed
44.
go back to reference Sandy JD, Flannery CR, Neame PJ, Lohmander LS: The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992, 89: 1512-1516. 10.1172/JCI115742.PubMedCentralCrossRefPubMed Sandy JD, Flannery CR, Neame PJ, Lohmander LS: The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992, 89: 1512-1516. 10.1172/JCI115742.PubMedCentralCrossRefPubMed
45.
go back to reference Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993, 36: 1214-1222. 10.1002/art.1780360906.CrossRefPubMed Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993, 36: 1214-1222. 10.1002/art.1780360906.CrossRefPubMed
46.
go back to reference Kraus VB, Nevitt M, Sandell LJ: Summary of the OA Biomarkers Workshop 2009 Biochemical Biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage. 2010, 18: 742-745. 10.1016/j.joca.2010.02.014.CrossRefPubMed Kraus VB, Nevitt M, Sandell LJ: Summary of the OA Biomarkers Workshop 2009 Biochemical Biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage. 2010, 18: 742-745. 10.1016/j.joca.2010.02.014.CrossRefPubMed
Metadata
Title
Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis
Authors
Staffan Larsson
Martin Englund
André Struglics
L Stefan Lohmander
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 6/2010
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3217

Other articles of this Issue 6/2010

Arthritis Research & Therapy 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.